Veteran U.K. Researcher Phil Lake to Head Theorem Clinical Research Biopharmaceutical Franchise in Respiratory

(King of Prussia, PA; September 10, 2013) — Theorem Clinical Research has promoted veteran U.K. researcher Phil Lake to head its biopharmaceutical franchise in respiratory. As executive director of biopharmaceutical development, respiratory, Lake will be responsible for senior oversight on major projects as well as building Theorem's respiratory business globally.

"Phil Lake has been a tremendous asset to our European operations, and I am confident he has the contacts and experience to take our biopharmaceuticals division to the next level," said Theorem President and CEO John Potthoff.

Prior to joining Theorem as senior director of project management in 2012, Lake held positions as the managing director of Springfield Clinical Consulting, as executive director of project management in Europe for Covance and as senior clinical research manager for GlaxoSmithKline in London. He has significant therapeutic experience in respiratory disorders, including numerous COPD and asthma studies.

Lake earned his bachelor's degree from University College Cardiff in Cardiff, U.K., and his Ph.D. from University of Southampton in Southampton, U.K.

About Theorem Clinical Research 

Theorem Clinical Research Inc. is a leading midsized provider of comprehensive clinical research and development services with offices in more than 30 countries and a customer base comprised of some of the world's top pharmaceutical, biotech and medical device companies. As a forerunner in medical device and drug-device combination trials with notable capabilities in pharmaceuticals and biologics, Theorem offers deep expertise in a broad range of therapeutic areas and in all phases of development. With some of the industry's top scientists and most advanced clinical analytics capabilities, Theorem ensures smooth-running, successful trials. For the full-service, right-size global research partner, don't think twice. THINK THEOREM. 

Suggested Articles

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Cour unveiled phase 2 data showing that its treatment cut levels of pro-inflammatory cytokines and protected the gut in patients with celiac disease.

Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics.